#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Oesophageal atresia Fusarium infection Antithrombin III deficiency Nephroblastoma Follicle centre lymphoma follicular grade I II – III refractory Cholangiosarcoma X-linked lymphoproliferative syndrome Urea cycle disorder Oesophageal achalasia Postprandial hypoglycaemia Albright's disease Extra-osseous Ewing's sarcoma Adult T-cell lymphoma/leukaemia refractory Polycystic liver disease Thromboangiitis obliterans More trials…

    Learn about Rare Diseases

    Paroxysmal nocturnal haemoglobinuria – Basic Information Aicardi-Goutieres syndrome – Trials in Disease Fragile X syndrome – Trials in Disease Noonan syndrome – Treatment Systemic sclerosis pulmonary – Trials in Disease Systemic mastocytosis – Life with Disease KBG syndrome – Life with Disease MELAS syndrome – Trials in Disease Sarcoidosis Pemphigoid – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Vinblastine Sulfate Quercetin Pralsetinib Cannabis Sativa Flower Fasudil Hydrochloride Oric-114 SILYMARIN IHMA-2121771-1 Radotinib Dihydrochloride Naproxen Sodium Lactulose Estradiol Hemihydrate ALE.P02 Lavender Oil Metoprolol Acou085 Isoniazid ATIRMOCICLIB Carbamazepine (Ph. Eur.) Ozanimod More therapies…

    Learn about Your Condition

    Lichen planus Herpes virus infection Pterygium Lennox-Gastaut syndrome Bone hypertrophy Thyroid mass Radius fracture Tooth loss Tympanic membrane hyperaemia Rheumatic disorder Gastrooesophageal cancer Metastases to biliary tract Lyme disease Delirium Ebola disease More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Post-acute COVID-19 syndrome

  • Study of FLUDEOXYGLUCOSE (18F) PET Imaging of Brain Metabolism in Patients with Persistent Post‑COVID Syndrome

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Post-acute COVID-19 syndrome
    Investigated Drugs:
    • Fludeoxyglucose (18F)
    The Netherlands

  • Total-Body PET with [18F]Flutemetamol in Patients with Post-COVID Syndrome (Long COVID)

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Post-acute COVID-19 syndrome
    Investigated Drugs:
    • Flutemetamol (18F)
    The Netherlands

  • Randomized trial of bupropion hydrochloride for fatigue in patients with long COVID (post‑COVID syndrome)

    Recruiting

    2 1 1
    Investigated Diseases:
    • Post-acute COVID-19 syndrome
    Investigated Drugs:
    • Bupropion Hydrochloride
    Germany

  • A Study of Sonlicromanol for Reducing Fatigue in Patients with Long COVID

    Recruiting

    2 1
    Investigated Drugs:
    • SONLICROMANOL HYDROCHLORIDE
    The Netherlands

  • A Study of Fluvoxamine for Reducing Fatigue in Patients with Post-COVID Condition

    Recruiting

    3 1 1
    Investigated Diseases:
    • Post-acute COVID-19 syndrome
    The Netherlands

  • Study on [68Ga]FAPI-46 to Detect Lung Fibroblast Activity in COVID-19 Patients with Long-Term Symptoms

    Recruiting

    3 1 1
    Investigated Diseases:
    • Post-acute COVID-19 syndrome
    Investigated Drugs:
    • (S)-2,2′,2”-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
    The Netherlands
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!